The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
MicroRNA Biomarkers in Whole Blood for Detection of Pancreatic Cancer
Open accessAbstract
IMPORTANCE: Biomarkers for the early diagnosis of patients with pancreatic cancer are needed to improve prognosis. OBJECTIVES: To describe differences in microRNA expression in whole blood between patients with pancreatic cancer, chronic pancreatitis, and healthy participants and to identify panels of microRNAs for use in diagnosis of pancreatic cancer compared with the cancer antigen 19-9 (CA19-9). DESIGN, SETTING, AND PARTICIPANTS: A case-control study that included 409 patients with pancreatic cancer and 25 with chronic pancreatitis who had been included prospectively in the Danish BIOPAC (Biomarkers in Patients with Pancreatic Cancer) study (July 2008-October 2012) plus 312 blood donors as healthy participants. The microRNA expressions in pretreatment whole blood RNA samples were collected and analyzed in 3 randomly determined subcohorts: discovery cohort (143 patients with pancreatic cancer, 18 patients with chronic pancreatitis, and 69 healthy participants), training cohort (180 patients with pancreatic cancer, 1 patient with chronic pancreatitis, and 199 healthy participants), and validation cohort (86 patients with pancreatic cancer, 7 patients with chronic pancreatitis, and 44 healthy participants); 754 microRNAs were screened in the discovery cohort and 38 microRNAs in the training cohort and 13 microRNAs in the validation cohort. MAIN OUTCOMES AND MEASURES: Identification of microRNA panels (classifiers) for diagnosing pancreatic cancer. RESULTS: The discovery cohort demonstrated that 38 microRNAs in whole blood were significantly dysregulated in patients with pancreatic cancer compared with controls. These microRNAs were tested in the training cohort and 2 diagnostic panels were constructed comprising 4 microRNAs in index I (miR-145, miR-150, miR-223, miR-636) and 10 in index II (miR-26b, miR-34a, miR-122, miR-126*, miR-145, miR-150, miR-223, miR-505, miR-636, miR-885.5p). The test characteristics for the training cohort were index I area under the curve (AUC) of 0.86 (95% CI, 0.82-0.90), sensitivity of 0.85 (95% CI, 0.79-0.90), and specificity of 0.64 (95% CI, 0.57-0.71); index II AUC of 0.93 (95% CI, 0.90-0.96), sensitivity of 0.85 (95% CI, 0.79-0.90), and specificity of 0.85 (95% CI, 0.80-0.85); and CA19-9 AUC of 0.90 (95% CI, 0.87-0.94), sensitivity of 0.86 (95% CI, 0.80-0.90), and specificity of 0.99 (95% CI, 0.96-1.00). Performances were strengthened in the validation cohort by combining panels and CA19-9 (index I AUC of 0.94 [95% CI, 0.90-0.98] and index II AUC of 0.93 [95% CI, 0.89-0.97]). Compared with CA19-9 alone, the AUC for the combination of index I and CA19-9 was significantly higher (P = .01). The performance of the panels in patients with stage IA-IIB pancreatic cancer was index I AUC of 0.80 (95% CI, 0.73-0.87); index I and CA19-9 AUC of 0.83 (95% CI, 0.76-0.90); index II AUC of 0.91 (95% CI, 0.87-0.94); and index II and CA19-9 AUC of 0.91 (95% CI, 0.86-0.95). CONCLUSIONS AND RELEVANCE: This study identified 2 diagnostic panels based on microRNA expression in whole blood with the potential to distinguish patients with pancreatic cancer from healthy controls. Further research is necessary to understand whether these have clinical implications for early detection of pancreatic cancer and how much this information adds to serum CA19-9.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer
Taylor, D. D., & Gercel-Taylor, C. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.04.033 · Cited by 2,288
RetractedSiegel, R., Naishadham, D., & Jemal, A. (2013) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21166 · Cited by 11,825
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Spencer, P. M., Cameron, J. L., & Lin, L. (2000) · Cited by 7,202
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712
Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012
Ferlay, J., Steliarova-Foucher, E., Lortet-Tieulent, J., Rosso, S., Coebergh, J. W. W., Comber, H., Forman, D., & Bray, F. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2012.12.027 · Cited by 5,263
Oettle, H., Neuhaus, P., Hochhaus, A., Hartmann, J. T., Gellert, K., Ridwelski, K., Niedergethmann, M., Zülke, C., Fahlke, J., Arning, M. B., et al. (2013) · JAMA · doi:10.1001/jama.2013.279201 · Cited by 1,794
Garzon, R., Calin, G. A., & Croce, C. M. (2009) · Annual Review of Medicine · doi:10.1146/annurev.med.59.053006.104707 · Cited by 1,770
ASCO 2006 Update of Recommendations for the Use of Tumor Markers in Gastrointestinal Cancer
Locker, G. Y., Hamilton, S., Harris, J., Jessup, J. M., Kemeny, N., Macdonald, J. S., Somerfield, M. R., Hayes, D. F., & Bast, R. C. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.2644 · Cited by 1,592
Transcriptional Activation of miR-34a Contributes to p53-Mediated Apoptosis
Raver-Shapira, N., Marciano, E., Meiri, E., Spector, Y., Rosenfeld, N., Moskovits, N., Bentwich, Z., & Oren, M. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.05.017 · Cited by 1,352
Bloomston, M., Frankel, W. L., Petrocca, F., Volinia, S., Alder, H., Hagan, J. P., Liu, C.-G., Bhatt, D., Taccioli, C., & Croce, C. M. (2007) · JAMA · doi:10.1001/jama.297.17.1901 · Cited by 1,141
MicroRNAs in Cancer: Small Molecules With a Huge Impact
Iorio, M. V., & Croce, C. M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.0317 · Cited by 959
Farazi, T. A., Spitzer, J. I., Morozov, P., & Tuschl, T. (2011) · The Journal of Pathology · doi:10.1002/path.2806 · Cited by 895
Blood Cell Origin of Circulating MicroRNAs: A Cautionary Note for Cancer Biomarker Studies
Pritchard, C. C., Kroh, E., Wood, B., Arroyo, J. D., Dougherty, K. J., Miyaji, M. M., Tait, J. F., & Tewari, M. (2012) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-11-0370 · Cited by 879 · cited 5×
“Age, median (range), y 54 (33-67) 56 (47-85)”
InfluentialSecreted microRNAs: a new form of intercellular communication
Chen, X., Liang, H., Zhang, J., Zen, K., & Zhang, C.-Y. (2012) · Trends in Cell Biology · doi:10.1016/j.tcb.2011.12.001 · Cited by 690
Haemolysis during sample preparation alters microRNA content of plasma
Kirschner, M. B., Kao, S. C., Edelman, J. J., Armstrong, N. J., Vallely, M. P., van Zandwijk, N., & Reid, G. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024145 · Cited by 569
Wang, J., Chen, J., Chang, P., LeBlanc, A., Li, D., Abbruzzesse, J. L., Frazier, M. L., Killary, A. M., & Sen, S. (2009) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-09-0094 · Cited by 559
Serum MicroRNA Expression Profile as a Biomarker in the Diagnosis and Prognosis of Pancreatic Cancer
Liu, R., Chen, X., Du, Y., Yao, W., Shen, L., Wang, C., Hu, Z., Zhuang, R., Ning, G., Zhang, C., et al. (2012) · Clinical Chemistry · doi:10.1373/clinchem.2011.172767 · Cited by 390
Combination of plasma microRNAs with serum CA19‐9 for early detection of pancreatic cancer
Liu, J., Gao, J., Du, Y., Li, Z., Ren, Y., Gu, J., Wang, X., Gong, Y., Wang, W., & Kong, X. (2012) · International Journal of Cancer · doi:10.1002/ijc.26422 · Cited by 309
MicroRNAs in normal and malignant hematopoiesis
Garzon, R., & Croce, C. M. (2008) · Current Opinion in Hematology · doi:10.1097/moh.0b013e328303e15d · Cited by 245
Zhang, J., Sun, Q., Zhang, Z., Ge, S., Han, Z.-G., & Chen, W.-T. (2013) · Oncogene · doi:10.1038/onc.2012.28 · Cited by 224
Analysis of MicroRNAs in Pancreatic Fine-Needle Aspirates Can Classify Benign and Malignant Tissues
Szafranska, A. E., Doleshal, M., Edmunds, H. S., Gordon, S., Luttges, J., Munding, J. B., Barth, R. J., Gutmann, E. J., Suriawinata, A. A., Marc Pipas, J., et al. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2008.109603 · Cited by 220
Xu, J., Zhu, X., Wu, L., Yang, R., Yang, Z., Wang, Q., & Wu, F. (2012) · Liver International · doi:10.1111/j.1478-3231.2011.02750.x · Cited by 215
Eichelser, C., Flesch-Janys, D., Chang-Claude, J., Pantel, K., & Schwarzenbach, H. (2013) · Clinical Chemistry · doi:10.1373/clinchem.2013.205161 · Cited by 195
Regulation of let-7 and its target oncogenes (Review)
WANG, X., CAO, L., WANG, Y., WANG, X., LIU, N., & YOU, Y. (2012) · Oncology Letters · doi:10.3892/ol.2012.609 · Cited by 193
Effect of microRNA‐34a in cell cycle, differentiation, and apoptosis: A review
Chen, F., & Hu, S. (2012) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.20412 · Cited by 189
Publication of Tumor Marker Research Results: The Necessity for Complete and Transparent Reporting
McShane, L. M., & Hayes, D. F. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.6858 · Cited by 185
Whole blood-derived miRNA profiles as potential new tools for ovarian cancer screening
Häusler, S. F. M., Keller, A., Chandran, P. A., Ziegler, K., Zipp, K., Heuer, S., Krockenberger, M., Engel, J. B., Hönig, A., Scheffler, M., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605833 · Cited by 178
MicroRNA expression profiles associated with pancreatic adenocarcinoma and ampullary adenocarcinoma
Schultz, N. A., Werner, J., Willenbrock, H., Roslind, A., Giese, N. A., Horn, T. D., Wøjdemann, M., & Johansen, J. S. (2012) · Modern Pathology · doi:10.1038/modpathol.2012.122 · Cited by 156
Self-citationThe role of microRNAs in normal and malignant hematopoiesis
Kuchenbauer, F. (2017) · Cited by 154
MiR-223 Suppresses Cell Proliferation by Targeting IGF-1R
Jia, C. Y., Li, H. H., Zhu, X. C., Dong, Y. W., Fu, D., Zhao, Q., Wu, W., & Wu, X. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027008 · Cited by 142
Bauer, A. S., Keller, A., Costello, E., Greenhalf, W., Bier, M., Borries, A., Beier, M., Neoptolemos, J. P., Büchler, M. W., Werner, J., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034151 · Cited by 128
MicroRNA Expression Profiles of Whole Blood in Lung Adenocarcinoma
Patnaik, S. K., Yendamuri, S., Kannisto, E. D., Kucharczuk, J. C., Singhal, S. K., & Vachani, A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046045 · Cited by 113
Circulating miR‐34a levels are reduced in colorectal cancer
Nugent, M., Miller, N., & Kerin, M. J. (2012) · Journal of Surgical Oncology · doi:10.1002/jso.23174 · Cited by 97
Plasma miR-216a as a potential marker of pancreatic injury in a rat model of acute pancreatitis
Kong, X. (2010) · World Journal of Gastroenterology · doi:10.3748/wjg.v16.i36.4599 · Cited by 66
Jung, C. J., Iyengar, S., Blahnik, K. R., Ajuha, T. P., Jiang, J. X., Farnham, P., & Zern, M. Α. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027740 · Cited by 65
Attia, J., Ioannidis, J. P. A., Thakkinstian, A., McEvoy, M., Scott, R. J., Minelli, C., Thompson, J., Infante-Rivard, C., & Guyatt, G. (2009) · JAMA · doi:10.1001/jama.2008.993 · Cited by 55
Jang, J.-Y., Lee, Y.-S., Jeon, Y., Lee, K., Jang, J., & Kim, C.-W. (2013) · Experimental & Molecular Medicine · doi:10.1038/emm.2013.1 · Cited by 45
How to Use an Article About Genetic Association
Attia, J., Ioannidis, J. P. A., Thakkinstian, A., McEvoy, M., Scott, R. J., Minelli, C., Thompson, J. R., Infante‐Rivard, C., & Guyatt, G. H. (2009) · Cited by 31
Cited by
Early Detection of Pancreatic Cancer: Opportunities and Challenges
Singhi, A. D., Koay, E. J., Chari, S. T., & Maitra, A. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.01.259 · Cited by 841
Cancer biomarker discovery and validation.
Goossens, N., Nakagawa, S., Sun, X., & Hoshida, Y. (2015) · PubMed · doi:10.3978/j.issn.2218-676x.2015.06.04 · Cited by 503
Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma
Grossberg, A. J., Chu, L. C., Deig, C. R., Fishman, E. K., Hwang, W. L., Maitra, A., Marks, D. L., Mehta, A., Nabavizadeh, N., Simeone, D. M., et al. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21626 · Cited by 489
Early screening and diagnosis strategies of pancreatic cancer: a comprehensive review
Yang, J., Xu, R., Wang, C., Qiu, J., Ren, B., & You, L. (2021) · Cancer Communications · doi:10.1002/cac2.12204 · Cited by 379
Pancreatic Cancer: A Review of Risk Factors, Diagnosis, and Treatment
Zhao, Z., & Liu, W. (2020) · Technology in Cancer Research & Treatment · doi:10.1177/1533033820962117 · Cited by 348
Metadata
- Authors
- Schultz, N. A., Dehlendorff, C., Jensen, B. V., Bjerregaard, J. K., Nielsen, K. R., Bojesen, S. E., Calatayud, D., Nielsen, S. E., Yilmaz, M., Holländer, N. H., Andersen, K. K., & Johansen, J. S.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2014-01-22
- Volume
- 311
- Issue
- 4
- Pages
- 392
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2019867275
- Cited by
- 450
- References
- 39
- FWCI
- 19.24
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.